SuPAR identifies patients at high risk of blood clot formation (Easy COVID test)

Medical Xpress / University of Michigan / Journal of the American Heart Association ^ | August 4, 2022 | Salim Hayek, M.D. et al

[ConservativeMind]

Blood clots occur in a third of patients hospitalized with COVID-19. In many cases these clots can be deadly, such as pulmonary embolisms—blood clots that travel to the lungs. In fact, in nearly one third of patients with COVID-19, these clots led to death.

An abnormal immune response is thought to be the major driver of severe COVID-19. One protein, called soluble urokinase plasminogen activator receptor, or suPAR, circulates in blood and originates from immune cells and has been shown to play a major role in complications of COVID-19.

"Traditionally, clinicians utilize D-dimer, a blood clot breakdown product, to assess activity," Luo said. "However, this marker has proven to be less predictive in COVID-19, as blood clot formation is in large part caused by a uniquely abnormal immune response to the virus."

Researchers measured D-dimer and suPAR levels over a 30-day period during patients' hospitalizations and diagnosed VTE (deep vein thrombosis and pulmonary embolism) using ultrasounds of the lower extremities and scans of the lungs.

Results showed that VTE occurred in 163 patients, and of those, 65 patients developed deep vein thrombosis, 88 patients developed a pulmonary embolus, and 10 patients developed both. Patients who developed blood clots had suPAR levels nearly 50% higher than those who did not develop clots. And, when suPAR levels were combined with D-dimer, researchers could classify 41% of study participants to have low-risk for occurrence of VTE.

Now that the association is made between suPAR levels and blood clot formation, clinicians could assess who is at high or low risk, which will help them decide what therapies to use to treat them. For example, someone at high risk could be given medications before blood clot formation.

Studying suPAR and its link to the immune system has positive implications within critical COVID-19 patients, and beyond.

[ConservativeMind]

These two tests, D-dimer and suPAR, should both be used to assess COVID clotting issues, unless your doctors are going to take daily ultrasounds of your whole body—which they obviously won’t.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20% fewer pings) or “Everything” list.

[Jumpmaster]

Is not “abnormal immune response” the definition of allergy?

[ProtectOurFreedom]

This sounds like a very helpful test. Is it widely available at labs? Is it inexpensive?

It’s been known from April 2020 that COVID is largely a vascular disease. Diminished lung function is due to vascular problems in the alveoli in the lungs and inhibited oxygen transport to the blood. The Chinese sure engineers a nasty weapon.

[ConservativeMind]

The suPAR test is available for labs.

“The suPAR level can be measured using the suPARnostic® product line. suPARnostic® is a CE-IVD certified antibody-based product range applied for quantitative measurements of suPAR in the clinical setting. Three product formats are available: 1) TurbiLatex, validated for clinical chemistry systems currently including the Roche Diagnostics cobas c501/2 and c701/2 systems; the Siemens ADVIA XPT and Atellica systems, and the Abbott Architect c and Alinity systems. 2) Quick Triage, which is a platform that is applied at the Point-Of-Care. 3) ELISA.”

https://en.m.wikipedia.org/wiki/Soluble_urokinase_plasminogen_activator_receptor